 | Up a level |
Kiryluk, Krzysztof; Sanchez-Rodriguez, Elena; Zhou, Xu-Jie; Zanoni, Francesca; Liu, Lili; Mladkova, Nikol; Khan, Atlas; Marasa, Maddalena; Zhang, Jun Y; Balderes, Olivia; Sanna-Cherchi, Simone; Bomback, Andrew S; Canetta, Pietro A; Appel, Gerald B; Radhakrishnan, Jai; Trimarchi, Hernan; Sprangers, Ben; Cattran, Daniel C; Reich, Heather; Pei, York; ... (2023). Genome-wide association analyses define pathogenic signaling pathways and prioritize drug targets for IgA nephropathy. Nature genetics, 55(7), pp. 1091-1105. Springer Nature 10.1038/s41588-023-01422-x
Scolari, Francesco; Delbarba, Elisa; Domenico, Santoro; Gesualdo, Loreto; Pani, Antonello; Dallera, Nadia; Mani, Laila-Yasmin; Santostefano, Marisa; Feriozzi, Sandro; Quaglia, Marco; Boscutti, Giuliano; Ferrantelli, Angelo; Marcantoni, Carmelita; Passerini, Patrizia; Magistroni, Riccardo; Alberici, Federico; Ghiggeri, Gian Marco; Ponticelli, Claudio; Ravani, Pietro (2021). Rituximab or Cyclophosphamide in the Treatment of Membranous Nephropathy: The RI-CYCLO Randomized Trial. Journal of the American Society of Nephrology : JASN, 32(4), pp. 972-982. American Society of Nephrology 10.1681/ASN.2020071091
Scolari, Francesco; Dallera, Nadia; Gesualdo, Loreto; Santoro, Domenico; Pani, Antonello; Santostefano, Marisa; Feriozzi, Sandro; Mani, Laila-Yasmin; Boscutti, Giuliano; Messa, Piergiorgio; Magistroni, Riccardo; Quaglia, Marco; Ponticelli, Claudio; Ravani, Pietro (2019). Rituximab versus steroids and cyclophosphamide for the treatment of primary membranous nephropathy: protocol of a pilot randomised controlled trial. BMJ open, 9(12), e029232. BMJ Publishing Group 10.1136/bmjopen-2019-029232
